Zacks Investment Research Upgrades uniQure NV (QURE) to “Hold”
uniQure NV (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other brokerages have also weighed in on QURE. Cowen and Company restated a “buy” rating on shares of uniQure NV in a research note on Thursday, June 2nd. Oppenheimer Holdings Inc. restated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Leerink Swann restated a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Jefferies Group restated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. uniQure NV presently has an average rating of “Buy” and a consensus target price of $28.10.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zacks-investment-research-upgrades-uniqure-nv-qure-to-hold.html
uniQure NV (NASDAQ:QURE) opened at 7.92 on Wednesday. The company has a 50 day moving average price of $8.23 and a 200-day moving average price of $10.38. The firm’s market capitalization is $199.02 million. uniQure NV has a 1-year low of $6.68 and a 1-year high of $28.99.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings data on Thursday, August 25th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.02. uniQure NV had a negative return on equity of 61.96% and a negative net margin of 537.62%. On average, analysts forecast that uniQure NV will post ($3.71) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares during the period. TFS Capital LLC raised its position in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares during the period. Princeton Alpha Management LP purchased a new position in shares of uniQure NV during the second quarter valued at approximately $120,000. Fox Run Management L.L.C. purchased a new position in shares of uniQure NV during the second quarter valued at approximately $122,000. Finally, Acrospire Investment Management LLC raised its position in shares of uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock valued at $127,000 after buying an additional 13,498 shares during the period. Hedge funds and other institutional investors own 32.38% of the company’s stock.
About uniQure NV
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.